ClinicalTrials.gg
CompletedNCT00244101Updated Jan 18, 2023Results posted

Delivery Room Management Trial of Premature Infants at High Risk of Respiratory Distress Syndrome

A Phase 3 interventional study of PS Group and NCPAP Group in Respiratory Distress Syndrome, Newborn, sponsored by Vermont Oxford Network. Completed at 1 site in United States. Open to participants aged 26 Weeks to 29 Weeks. Per ClinicalTrials.gov, last updated 2023-01-18.

Sponsored by Vermont Oxford Network · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
648
Allocation
Randomized
Ages
26 Weeks to 29 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Respiratory Distress Syndrome, Newborn with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Respiratory Distress Syndrome, Newborn · United States.

Enrollment
3rd of 29
648 · median 93
Started
2003
the only one that year
Phase 3
3 of 34
none open now
Registered
6th of 34
by date

Among the 34 studies in Respiratory Distress Syndrome, Newborn with a site in United States, this one is the 3rd largest by enrollment of the 29 interventional ones that give a count, is the only one that started in 2003, is one of 3 in phase 3, and was the 6th registered.

Respiratory Distress Syndrome, Newborn

123 studies on the registry are indexed under Respiratory Distress Syndrome, Newborn; 24 are open to participants now.

Browse Respiratory Distress Syndrome, Newborn studies →

Open to participants now

5 of the 34 studies in Respiratory Distress Syndrome, Newborn with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Respiratory Distress Syndrome, Newborn studies recruiting now, 2 (17%) set no upper age limit and 10 (83%) stop at 75 or younger; 12 take children under 18; 2 take healthy volunteers.

This study: 26 Weeks to 29 Weeks · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Respiratory Distress Syndrome, Newborn with a site in United States, or all of them as a file.
02

Study summary

The best mode of delivery room stabilization for premature infants at high risk for respiratory distress syndrome is unknown. The protocol evaluates the impact of three distinct methods of post-delivery stabilization and subsequent early respiratory care on chronic lung disease and survival in premature infants at high risk for respiratory distress syndrome.

Read the detailed description

The "Delivery room management of premature infants at high risk of respiratory distress syndrome" protocol compares three distinct methods of post-delivery stabilization and subsequent early respiratory care on chronic lung disease and survival in premature infants at high risk of respiratory distress syndrome. The three approaches to post-delivery care include:

  1. Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support.
  2. Early stabilization on nasal continuous positive airway pressure (NCPAP) with selective intubation and surfactant administration for clinical indications.
  3. Intubation, prophylactic surfactant administration shortly after delivery and rapid extubation to nasal CPAP.

The primary null hypothesis for this study is that no difference will be found in chronic lung disease and/or mortality at 36 weeks adjusted age in premature infants at high risk of RDS, depending on the method of post-delivery stabilization.

The study is a randomized, multicenter trial conducted at participating Vermont Oxford Network Centers. Participating centers will demonstrate competency in the use of nasal CPAP by successfully completing a web-based, educational program and utilizing nasal CPAP in a minimum of 20 infants in their NICU.

Infants likely to be delivered to women presenting to a participating Vermont Oxford Network Center at high risk of premature delivery at gestational age 26 + 0 to 29 + 6 weeks will be eligible for inclusion. Specific inclusion criteria that must be met prior to randomization include:

  1. imminent delivery
  2. no potentially life-threatening congenital anomaly or genetic syndrome
  3. no known lung maturity
  4. antenatal steroid status known
  5. written and informed consent obtained prior to delivery.

Exclusion criteria will include:

  1. stillborn infants (Apgar score of 0 at one minute of age) or
  2. infants noted to have a potentially life-threatening congenital anomaly or genetic syndrome noted immediately after delivery.

Eligible infants will have consent obtained prior to delivery. They will be stratified into two groups: 26 + 0 to 27 + 6 weeks gestation and 28 + 0 to 29 + 6 weeks gestation. Shortly before delivery, infants will be randomized to one of the three stabilization strategies detailed below:

  1. Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support (PS group).
  2. Early stabilization on nasal continuous positive airway pressure (NCPAP) with selected intubation and surfactant administration for clinical indications (NCPAP group).
  3. Intubation, prophylactic surfactant administration shortly after delivery, and rapid extubation to nasal CPAP (ISX group).

Infants requiring intubation for respiratory failure during this study (in any of the three groups) may be stabilized on either conventional or high-frequency ventilation. Specific criteria regarding target ranges for blood gases and indications for extubation, subsequent surfactant dosing, management of extubation, and criteria for reintubation, are all detailed in the protocol.

The primary outcome measure is chronic lung disease (defined as documented requirement for supplemental oxygen or respiratory support) or mortality at 36 weeks adjusted age. Secondary outcome measures include a variety of clinical outcomes, as well as issues regarding duration of hospital stay and other resource utilization. Long-term outcomes will be measured by a health care questionnaire at two years of age. A sample size of over 895 infants will be required to demonstrate a 25% reduction in the risk of chronic lung disease at 36 weeks adjusted age.

03

Conditions studied

  • Respiratory Distress Syndrome, Newborn

Keywords

  • Prematurity
  • respiratory distress syndrome
  • surfactant
  • nasal continuous positive airway pressure
04

Who can participate

Ages eligible
26 Weeks to 29 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Infants likely to be delivered to women presenting to a participating Vermont Oxford Network Center at high risk of premature delivery at gestational age 26 + 0 to 29 + 6 weeks will be eligible for inclusion. Specific inclusion criteria that must be met prior to randomization include:

  1. Imminent delivery
  2. No potentially life-threatening congenital anomaly or genetic syndrome
  3. No known lung maturity
  4. Antenatal status known
  5. Written, obtained (on admission or prior to delivery).

Exclusion criteria

Exclusion Criteria:

  1. Stillborn (Apgar score of 0 at one minute of age)
  2. Noted to have a potentially life-threatening congenital anomaly or genetic syndrome noted immediately after delivery.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
648 participants (actual)

Study arms

  • Active comparator
    PS Group

    Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support.

    Drug: PS Group

  • Experimental
    NCPAP Group

    Early stabilization on nasal continuous positive airway pressure (NCPAP) with selected intubation and surfactant administration for clinical indications.

    Device: NCPAP Group

  • Experimental
    ISX Group

    Intubation, prophylactic surfactant administration shortly after delivery, and rapid extubation to nasal CPAP.

    Drug: ISX Group

Interventions

  • DrugPS Group

    Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support.

    Also known as: Prophylactic Surfactant Group

  • DeviceNCPAP Group

    Early stabilization on nasal continuous positive airway pressure (NCPAP) with selected intubation and surfactant administration for clinical indications.

    Also known as: Nasal CPAP group

  • DrugISX Group

    Intubation, prophylactic surfactant administration shortly after delivery, and rapid extubation to nasal CPAP.

    Also known as: Intubation, Surfactant Administration, Extubation to Nasal CPAP. ENSURE.

06

What researchers measure

Primary outcomes

  1. Death or Chronic Lung Disease

    Time frame: at 36 weeks postmenstrual age

  2. Death

    Time frame: 36 weeks adjusted age

07

Results

Posted Sep 14, 2012
Limitations and caveats
The study was stopped after recruitment reached 74% of the projected sample size because of difficulties with enrollment. Because this study could not be blinded, there was a possibility of bias influencing the outcomes if providers managing the infants did not follow strict guidelines.

Participant flow

Participant flow — Overall Study
MilestonePS GroupNCPAP GroupISX Group
Started209223216
Completed209223216
Not completed000

Outcome measures

PrimaryDeath or Chronic Lung Disease
Time frame:
at 36 weeks postmenstrual age
Reported as:
Number · participants
Death or Chronic Lung Disease
participantsPS GroupNCPAP GroupISX Group
Death or Chronic Lung Disease766862
Statistical analysis
  • PS Group vs ISX Group · Risk ratio (rr): 0.78 · 95% CI 0.59 to 1.03
  • PS Group vs NCPAP Group · Risk ratio (rr): 0.57 · 95% CI 0.25 to 1.27
PrimaryDeath
Time frame:
36 weeks adjusted age
Reported as:
Count of participants · Participants
Death
ParticipantsPS GroupNCPAP GroupISX Group
Death15915
Statistical analysis
  • PS Group vs ISX Group · Risk ratio (rr): 0.97 · 95% CI 0.49 to 1.94
  • PS Group vs NCPAP Group · Risk ratio (rr): 0.83 · 95% CI 0.64 to 1.09

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Prophylactic Surfactant—0/209 (0%)0/209 (0%)
Surfactant Extubated to nCPAP—0/216 (0%)0/216 (0%)
NCPAP—0/223 (0%)0/223 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PS GroupNCPAP GroupISX GroupTotal
<=18 years209223216648
Between 18 and 65 years0000
>=65 years0000
Age, Continuous
Age, Continuous(weeks of gestation)PS GroupNCPAP GroupISX GroupTotal
Mean28.0 ± 1.128.1 ± 1.328.1 ± 1.128.0 ± 1.1
Sex: Female, Male
Sex: Female, Male(Participants)PS GroupNCPAP GroupISX GroupTotal
Female11899115332
Male91124101316
Region of Enrollment
Region of Enrollment(participants)PS GroupNCPAP GroupISX GroupTotal
United States209223216648
08

Study locations

1 site
  • Vermont Oxford Network
    Burlington, Vermont 05401, United States
09

References and documents

Publications

  • Dunn MS, Kaempf J, de Klerk A, de Klerk R, Reilly M, Howard D, Ferrelli K, O'Conor J, Soll RF; Vermont Oxford Network DRM Study Group. Randomized trial comparing 3 approaches to the initial respiratory management of preterm neonates. Pediatrics. 2011 Nov;128(5):e1069-76. doi: 10.1542/peds.2010-3848. Epub 2011 Oct 24. PubMed 22025591 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2003, a primary completion of Jun 2009 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2012, 3 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2005
First posted
Oct 25, 2005
Start
Aug 2003
Primary completionActual
Jun 2009
CompletionActual
Jun 2011
Results first posted
Sep 14, 2012
Last update
Jan 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00244101
Lead sponsor
Vermont Oxford Network
Responsible party
Sponsor
First posted
Oct 25, 2005
Start date
Aug 2003
Primary completion
Jun 2009
Completion
Jun 2011
Results posted
Sep 14, 2012
Last update
Jan 18, 2023

Study contacts

Roger F Soll, MD
principal investigator · Vermont Oxford Network
Michael Dunn, MD
principal investigator · Sunnybrook and Women's Hospital, Toronto, Ontario, Canada

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion